

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 December 2003 (24.12.2003)

PCT

(10) International Publication Number
WO 03/105822 A1

(51) International Patent Classification⁷: **A61K 31/20**

(21) International Application Number: **PCT/IB03/02317**

(22) International Filing Date: **16 June 2003 (16.06.2003)**

(25) Filing Language: **Italian**

(26) Publication Language: **English**

(30) Priority Data:
TO2002A000521 17 June 2002 (17.06.2002) IT
TO2002A001049 3 December 2002 (03.12.2002) IT

(71) Applicant (for all designated States except US):
MEDESTEA RESEARCH & PRODUCTION S.R.L.
[IT/IT]; Via Ribes 5, I-10010 Colletterto Giacosa (IT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **CRAVOTTO, Gian-**
cario [IT/IT]; Via Buenos Aires 106, I-10137 Torino (IT).

(74) Agents: **RAMBELLI, Paolo** et al.; Jacobacci & Partners
SpA, Corso Regio Parco 27, I-10152 Torino (IT).

(81) Designated States (national): AE, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

-- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW. ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

-- of inventorship (Rule 4.17(iv)) for US only

Published:

-- with international search report
-- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **LONG CHAIN UNSATURATED OXYGENATED COMPOUNDS AND THEIR USE IN THE THERAPEUTICAL, COSMETIC AND NUTRACEUTICAL FIELD**

(57) Abstract: Long-chain unsaturated oxygenated compounds and their use in the therapeutic, cosmetic and nutraceutical field. Use of compounds of formula R-X wherein X is a primary alcoholic functional group -CH₂OH, a carboxylic functional group -COOH or a C1-C4 alkyl ester group, and of mono-, di- and tri-glycerides of acid compounds R-COOH and of pharmaceutically acceptable salts of those acids, wherein R is a hydrocarbon chain having from 19 to 35 carbon atoms, which is saturated or unsaturated, including from one to five ethylenic or acetylenic unsaturations, linear or branched, including from one to five methyl branches, and optionally substituted by from one to three hydroxyl groups, for the preparation of pharmaceutical or nutraceutical compositions useful for the treatment and prevention of pathologies related to a high concentration of cholesterol and lipids, pathologies associated with an increased ability of the blood platelets to aggregate and with a reduced concentration of oxygen, in the treatment of ageing processes, for the preparation of compositions of nutritional integrators aimed at weight loss and cosmetic compositions useful in the treatment and prevention of skin damage caused by free radicals.

WO 03/105822 A1

Long-chain unsaturated oxygenated compounds and their use in the therapeutical, cosmetic and nutraceutical field

The present invention relates to novel uses in the therapeutic, cosmetic and nutraceutical field of alcohols, acids and esters of those acids having a long mono- or poly-unsaturated hydrocarbon chain.

The novel uses and the compounds forming the subject-matter of the invention are defined in the claims which follow.

In particular, the novel uses to which the invention relates concern compounds of formula $R-X$, wherein X is an optionally salified primary alcoholic $-CH_2OH$ or carboxylic $-COOH$ functional group or an esterified carboxylic group $-COOR_3$, wherein R_3 is C_1-C_4 alkyl, preferably ethyl or propyl (and glyceride esters of those acids), and wherein R is a hydrocarbon chain having from 19 to 35 carbon atoms, preferably from 23 to 35 and more preferably from 25 to 31 carbon atoms, and including one or more ethylenic or acetylenic unsaturations, preferably from one to five unsaturations; the hydrocarbon chain R is preferably a linear or, optionally, a branched chain, including from one to five methyl branches, which chain may optionally be substituted by one or more hydroxy groups, for example, by from one to three hydroxy groups.

The invention is also directed to a preferred class of compounds which is constituted by compounds of the general formula $R_2 = R_1-X$, wherein X has the meaning mentioned above and wherein R_1 and R_2 have a total of from 23 to 35 carbon atoms, preferably from 25 to 31 carbon atoms, and R_1 is a saturated linear hydrocarbon chain having from 4 to 15, preferably from 7 to 13 carbon atoms and R_2 is a hydrocarbon chain having from 8 to 22, preferably from 10 to 20 carbon atoms, which is saturated or unsaturated, including from one to four ethylenic or acetylenic unsaturations, and preferably linear

or optionally branched, including from one to four methyl branches, and optionally substituted by hydroxy, for example, by from one to three hydroxy groups.

Even more preferred are compounds wherein R_1 is a linear saturated hydrocarbon chain having 9 carbon atoms and compounds wherein R_2 is the hydrocarbon chain of a saturated or unsaturated naturally occurring fatty acid, such as, for example, the hydrocarbon chain of oleic, lineoleic, linolenic, ricinoleic or farnesyllic acid.

The compounds according to the invention can be prepared by synthesis processes known in the literature, in particular by the process described in TO2002A000521 in the name of the applicant, the description of which is to be regarded as incorporated herein by reference.

This process comprises a Wittig olefination reaction (cf. Merck Index, XII ed., ONR-99 and references mentioned therein) in which a phosphorus ylide ($R''P(Ar)_3$) - wherein R'' is a saturated or unsaturated hydrocarbon chain including one or more ethylenic or acetylenic unsaturations and wherein Ar is phenyl - is reacted with an n-alkanoic acid $R'COOH$ oxo-substituted in the terminal position or with the C_1 - C_4 alkyl ester of that oxo-substituted alkanoic acid to give the addition product constituted by the alkenoic acid $R'' = R'-COOH$ or its alkyl ester (where the term alkenoic refers to the presence of the ethylenic unsaturation introduced as a result of the Wittig reaction), having the desired chain length.

The number of carbon atoms in the group R'' of the above-mentioned phosphorus ylide may vary within wide limits and in particular R'' may coincide with the group R_2 defined above.

Similarly, the length of the chain R' of the above-mentioned n-alkanoic acid, which is formylated in the terminal position, or its alkyl ester may vary within wide limits and may

be selected as a function of the position in which the desired compound has the first double bond.

In particular R' may have a number of carbon atoms corresponding to the definition of R_1 given above and more particularly may be 10-oxo-decanoic acid or the corresponding lower alkyl (preferably ethyl) 10-oxo-decanoate.


The phosphorus ylide $R''P(Ar)_3$ is prepared by reacting the corresponding halogen derivative (where halogen is preferably bromine or chlorine) with triphenylphosphine, preferably in an aromatic solvent (toluene) while heating under reflux; at the end of the reaction, the solution is concentrated and the phosphonium salt is precipitated, preferably with ether.

Because in the Wittig reaction described above it is preferable to use as reagent the alkyl ester, formylated in the terminal position, of an n-alkanoic acid, the process leads directly to the preparation of unsaturated compounds, used within the scope of the invention, having an ester functionality. The corresponding unsaturated acids can be obtained from the ester by alkaline hydrolysis and the corresponding compounds having a primary alcohol functionality by reduction of the ester, for example, with lithium aluminium hydride.

The process for preparing compounds used within the scope of the invention is further illustrated by the following Examples.

Example 1 - Preparation of the ethyl ester of octacos-10,19-dienoic acid

The synthesis process is illustrated in the following scheme and the associated operating stages are described in Examples 1a-1d which follow.



NMO: N-methylmorpholine N-oxide

Example 1a - Ethyl ester of undecylenic acid

In a 100 ml two-necked flask, 8 ml of ethanol and a spatula tip of *p*-toluenesulphonic acid are added to 15 g of undecylenic acid (81.4 mmol) dissolved in 35 ml of anhydrous toluene. The whole is heated under reflux for 8 hours with a Dean Stark or Markusson distilling apparatus separating the water of esterification. All of the glassware used has previously been dried in an oven at 120°C. The progress of the reaction is monitored by TLC (silica gel plates), eluant hexane/EtOAc 7:3. R_f ester = 0.67.

Work-up: the product is diluted with EtOAc, washed twice with a mixture of $\text{NaHCO}_3/\text{H}_2\text{O}$ 1:1, then with H_2O and a saturated NaCl solution and dried over Na_2SO_4 . 16.7 g (78.9 mmol) are obtained (Yield 97%). Any traces of starting acid can be eliminated by filtration over a bed of alumina.

Example 1b - ethyl 10-oxodecanoate

In a 500 ml flask, 2.5 ml of a 0.2 M solution of OsO_4 in toluene (0.005 eq; 1.03 mmol) and 24.13 g of *N*-methylmorpholine-*N*-oxide (1 eq) are added to 43.67 g of the ethyl ester of undecylenic acid (0.206 mmol) dissolved in 100 ml of a 1:1 H_2O /acetone mixture. The whole is left under agitation for fifteen minutes at 0°C in ice. 79.31 g of NaIO_4 (1.8 eq; 0.37 mmol) are then added in small portions over a period of 40 minutes at ambient temperature. The reaction is followed by TLC (silica gel plates), eluant hexane/EtOAc 7:3 R_f product = 0.5.

Work-up: the product is filtered on a funnel having a sintered porous baffle, diluted with EtOAc, washed with a saturated NaCl solution and dried over Na_2SO_4 . The product is then purified on a chromatographic column of silica gel (CC) eluant hexane/EtOAc 9:1. 38.3 g of ethyl 10-oxodecanoate (179.2 mmol) are obtained. (Yield 87%).

Example 1c - Phosphonium salt of *cis* 1-bromo-9-octadecene

In a 250 ml flask, 1 eq of triphenylphosphine (24.6 g) is added to 29.8 g of *cis* 1-bromo-9-octadecene (0.09 mmol) dissolved in 80 ml of anhydrous toluene. The whole is heated under reflux in a heating jacket for 24 hours. It is cooled in a bath of water and ice for approximately 10 minutes and then approximately 15 ml of diethyl ether are added. The phosphonium salt precipitates in abundance and is filtered on a funnel having a sintered porous baffle and is washed with approximately 50 ml of ether. 40.9 g of a pearly pink solid (71.2 mmol) are obtained. (Yield 80%).

Example 1d - Ethyl ester of octacos-10,19-dienoic acid

In a 1 l two-necked flask, 31.9 g of phosphonium salt (56.0 mmol) are dissolved in 350 ml of anhydrous THF with magnetic agitation in a nitrogen atmosphere. All the glassware used has previously been dried in an oven at 120°C . 1.05 eq of

BuLi solution (1.6 M in hexane) (34 ml) are slowly added dropwise; the reaction mixture progressively becomes an orange-red colour, which indicates the formation of the ylide. After approximately 20 minutes, 5 ml of a solution containing 10.78 g of ethyl 10-oxo-decanoate (0.9 eq; 50.4 mmol) are slowly added dropwise; during the addition of the aldehyde, the colour of the solution becomes yellow-orange. The whole is left under magnetic agitation overnight. The reaction is monitored by TLC (silica gel plates), eluant hexane/EtOAc 9:1. R_f product = 0.67.

Work-up: the product is diluted with a 0.1N HCl solution and extracted with EtOAc; washing is effected with a saturated NaCl solution and drying is effected over Na_2SO_4 . 20.2 g of product (45.1 mmol) are obtained. (Yield 90%).

Example 2 - Octacos-10,19-dienoic acid

In a 100 ml flask, 5.3 g of the ethyl ester of octacos-10,19-dienoic acid (11.8 mmol) in admixture with an aqueous 3.5N NaOH solution (30 ml) are heated at 90°C for 2 hours. The reaction is monitored by TLC (silica gel plates), eluant hexane/EtOAc 8:2. R_f product = 0.30.

Work-up: the mixture is acidified with 1N HCl and extracted with CH_2Cl_2 . The organic phase is washed with a saturated NaCl solution and dried over Na_2SO_4 . 4.7 g of octacos-10,19-dienoic acid (11.2 mmol) are obtained. (Yield 95%).

Example 3 - Octacos-10,19-dienol

The alcohol mentioned above can be obtained from the ethyl ester of octacos-10,19-dienoic acid (Example 1d) by reduction, for example with lithium aluminium hydride.

Example 4 - Octacos-10,19,22-trienoic acid

The acid mentioned above, its corresponding ester (preferably

ethyl ester) and the corresponding primary alcohol can be prepared by following the procedure described in Examples 1-3, using as reagent in the Wittig reaction the phosphonium salt of 1-bromo-9,12-octadecadiene (derivative of linoleic alcohol).

Example 5 - Octacos-10,19,22,25-tetraenoic acid

The acid mentioned above, its corresponding ester (preferably ethyl ester) and the corresponding primary alcohol can be prepared by following the procedure described in Examples 1-3, using as the starting compound in the Wittig reaction the phosphonium salt of 1-bromo-9,12,15-octadecatriene (derivative of linolenic alcohol).

Example 6 - 14,18,22-trimethyltricos-10,13,17,21-tetraenoic acid

The acid mentioned above, its corresponding ester (preferably ethyl ester) and the corresponding primary alcohol can be prepared by following the procedure of Examples 1-3, using in the Wittig reaction the phosphonium salt of 1-bromo-3,7,11-trimethyl-2,6,10-dodecatriene (derivative of farnesol).

In general, the compounds described have a better activity than do the corresponding polycosanols and polycosanoic acids and can therefore be used advantageously in the pharmaceutical, cosmetic and nutritional field (particularly for dietetic nutritional integrators) in which the polycosanols and polycosanoic acids are typically used.

The compounds described have a high degree of anti-oxidant activity and a high degree of activity in the capture of free radicals, which enables them to be used both in cosmetic and nutritional compositions as anti-oxidants, in order to prevent the oxidative deterioration of those compositions, and in cosmetic and dermatological compositions for topical use,

for the prevention and treatment of skin damage caused by free radicals, such as, in particular, for the treatment and prevention of inflammatory and ageing effects of the skin.

The compounds are also characterized by a higher hypocholesterolaemic and/or hypolipidaemic activity in addition to a favourable effect on the lipoprotein picture (increase in HDL) compared with the corresponding polycosanols; they are therefore suitable for use in the preparation of medicaments and pharmaceutical compositions useful for the treatment and prevention of pathologies related to hypercholesterolaemia and hyperlipidaemia, such as, for example, cardiovascular diseases of the ischaemic or atherosclerotic type and peripheral vascular diseases, and also for the prevention and cure of pathologies associated with an increased ability of the blood platelets to aggregate and with reduced oxygenation and nutrition of tissue, such as, for example, peripheral neuropathies and, in particular, diabetic peripheral neuropathy.

The compounds described have exhibited a high degree of activity in restoring the membrane fluidity of ghost cells or blood platelets and in improving the anti-oxidant defences of the plasma, liver, brain and heart.

Pharmaceutical compositions containing those compounds are therefore useful in general in the treatment of ageing processes, including cerebral ageing and degenerative brain diseases, such as Alzheimer's disease, Parkinson's disease, senile dementia, loss of memory and confused states, and also conditions of stress and depression.

A further use of the compounds described is in the therapeutic treatment and the prevention of obesity, and also in compositions of dietetic nutritional integrators aimed at weight loss and the prevention and treatment of cellulite.

The compounds described can also be used in the preparation

of compositions of nutritional integrators intended for strengthening muscle and suitable for increasing physical fitness in humans and animals.

The forms of administration for pharmaceutical compositions and dietetic integrators are preferably forms of administration by the oral route, such as, in particular, tablets, pastilles and capsules, including vehicles and/or excipients that are pharmaceutically acceptable and for nutritional use.

The compounds can also be used in compositions comprising other active ingredients, in particular anti-oxidant vitamins, such as vitamin E, lipoic acid, vitamin C, vitamin B6, vitamin B12.

Also useful is the utilisation of the compounds in association with L-carnitine or an alkanoyl derivative thereof, particularly in the treatment of the above-mentioned pathologies caused by altered lipid metabolism.

The compounds having an acid functionality may be used in the form of pharmaceutically acceptable salts or in the form of tri-, di- and mono-glycerides, esters of phospholipids or also as salts with amino acids (such as, for example, arginine, lysine, methionine, cysteine and the like).

CLAIMS

1. Use of compounds of formula R-X wherein X is a primary alcoholic functional group $-CH_2OH$, a carboxylic functional group $-COOH$ or a C_1-C_4 alkyl ester group, and of mono-, di- and tri-glycerides of acid compounds R-COOH and of pharmaceutically acceptable salts of those acids, wherein R is a hydrocarbon chain having from 23 to 35 carbon atoms, which is saturated or unsaturated, including from one to five ethylenic or acetylenic unsaturations, linear or branched, including from one to five methyl branches, and optionally substituted by from one to three hydroxyl groups, for the preparation of pharmaceutical or nutraceutical compositions useful for the treatment and prevention of pathologies related to a high concentration of cholesterol and lipids, and pathologies associated with an increased ability of blood platelets to aggregate and with a reduced concentration of oxygen.

2. Use of compounds of formula R-X wherein X is a primary alcoholic functional group $-CH_2OH$, a carboxylic functional group $-COOH$ or a C_1-C_4 alkyl ester group, and of mono-, di- and tri-glycerides of acid compounds R-COOH and of pharmaceutically acceptable salts of those acids, wherein R is a hydrocarbon chain having from 19 to 35 carbon atoms, which is saturated or unsaturated, including from one to five ethylenic or acetylenic unsaturations, linear or branched, including from one to five methyl branches, and optionally substituted by from one to three hydroxyl groups for the preparation of pharmaceutical or nutraceutical compositions useful for the treatment and prevention of peripheral vascular diseases and peripheral neuropathies.

3. Use of compounds as defined in claim 1, for the preparation of pharmaceutical or nutraceutical compositions useful in the treatment or prevention of atherosclerosis, hypercholesterolaemia, cardiovascular diseases of the ischaemic or

atherosclerotic type, peripheral vascular diseases and peripheral neuropathies.

4. Use of compounds according to claim 1, for the preparation of pharmaceutical or nutraceutical compositions useful in the treatment of ageing processes in humans, in particular cerebral ageing and degenerative brain diseases.

5. Use of compounds according to claim 1, for the preparation of pharmaceutical or nutraceutical compositions useful for restoring the membrane fluidity of ghost cells and blood platelets.

6. Use of compounds according to claim 1, for the preparation of compositions of nutritional integrators aimed at weight loss, the prevention and treatment of cellulite, the strengthening of muscle and the improvement of physical fitness in humans and animals.

7. Use of compounds according to claim 1, for the preparation of cosmetic compositions useful in the treatment and prevention of skin damage caused by free radicals.

8. Use according to any one of claims 1 to 7, wherein the compounds comprise from 25 to 31 carbon atoms.

9. Use according to any one of claims 1 to 7, wherein the compounds are of the general formula $R_2 = R_1-X$, wherein X has the meaning defined above and wherein R_1 and R_2 have a total of from 23 to 35 carbon atoms, preferably from 25 to 31 carbon atoms, and R_1 is a saturated linear hydrocarbon chain having from 4 to 15 carbon atoms and R_2 is a hydrocarbon chain having from 8 to 22 carbon atoms which is saturated or unsaturated, including from one to four ethylenic or acetylenic unsaturations, linear or optionally branched, including from one to four methyl branches, and optionally substituted by from one to three hydroxyl groups.

10. Use of compounds as defined in claim 9, wherein R_1 is a hydrocarbon chain having from 7 to 13 carbon atoms and R_2 is a hydrocarbon chain having from 10 to 20 carbon atoms.

11. Use according to claim 9 or 10, wherein R_1 is a linear hydrocarbon chain having 9 carbon atoms and R_2 is the chain of a saturated or unsaturated naturally occurring fatty acid.

12. Use according to claim 10, wherein R_2 is a hydrocarbon chain of oleic, linoleic, linolenic, ricinoleic or farnesylic acid.

13. Compounds of the general formula $R_2=R_1-X$, wherein X is a primary alcoholic functional group $-CH_2OH$, a carboxylic functional group $-COOH$ or a C_1-C_4 alkyl ester group, wherein R_1 and R_2 have a total of from 23 to 35 carbon atoms and R_1 is a saturated linear hydrocarbon chain having from 4 to 15 carbon atoms and R_2 is a hydrocarbon chain having from 8 to 22 carbon atoms which is saturated or unsaturated, including from one to four ethylenic and/or acetylenic unsaturations, linear or optionally branched, including from one to four methyl branches, and optionally substituted by from one to four hydroxyl groups, their pharmaceutically acceptable salts and mono-, di- and tri-glycerides of acids $R_2 = R_1-COOH$.

14. Compounds according to claim 13, wherein R_1 is a hydrocarbon chain having from 7 to 13 carbon atoms and R_2 is a hydrocarbon chain having from 10 to 20 carbon atoms.

15. Compounds according to claim 13 or 14, wherein R_1 is a saturated linear hydrocarbon chain having 9 carbon atoms.

16. Compounds according to any one of claims 12 to 15, wherein R_2 is the hydrocarbon chain of a naturally occurring fatty acid.

17. Compounds according to claims 13 to 16, selected from the

group consisting of:

- octacos-10,19-dienoic acid,
- octacos-10,19,22-trienoic acid,
- octacos-1,19,22,25-tetraenoic acid,
- 14,18,22-trimethyltricos-10,13,17,21-tetraenoic acid,
- corresponding primary alcohols, and
- C₁-C₄ alkyl ester of those acids.

18. Compounds according to claim 17, in the form of the ethyl ester.

19. Pharmaceutical, nutraceutical, dietetic integrator or cosmetic compositions including a compound as defined in claims 1, 8 or 13 to 18 in association with anti-oxidant vitamins, carnitine or its alkanoyl derivative.

INTERNATIONAL SEARCH REPORT

International Application No. .

PCT/IB 03/02317

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, CHEM ABS Data, BIOSIS, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 1 106 181 A (MORINAGA MILK INDUSTRY CO LTD) 13 June 2001 (2001-06-13) claim 1; tables 3,8	1-19
A	US 5 502 077 A (BONAA KAARE H ET AL) 26 March 1996 (1996-03-26) claim 1	1-19
A	US 5 656 667 A (DAHL KNUT HELKAAS ET AL) 12 August 1997 (1997-08-12) claim 1	1-19
A	US 5 698 594 A (BOENAA KAARE HARALD ET AL) 16 December 1997 (1997-12-16) claim 1	1-19

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

C document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

S document member of the same patent family

Date of the actual completion of the international search

28 October 2003

Date of mailing of the international search report

03/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5010 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Beyss, E

INTERNATIONAL SEARCH REPORT

International Publication No.
PCT/IB 03/02317

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 1106181	A	13-06-2001	CA 2340223 A1 24-02-2000 EP 1106181 A1 13-06-2001 WO 0009138 A1 24-02-2000
US 5502077	A	26-03-1996	US 5656667 A 12-08-1997 US 5698594 A 16-12-1997 AT 398779 B 25-01-1995 AT 191889 A 15-06-1994 AU 616784 B2 07-11-1991 AU 3896789 A 15-02-1990 BE 1002547 A5 19-03-1991 CA 1337548 C 14-11-1995 CH 680789 A5 13-11-1992 DE 3926658 A1 15-02-1990 DK 392089 A 12-02-1990 ES 2018384 A6 01-04-1991 FI 893805 A 12-02-1990 FR 2635263 A1 16-02-1990 GB 2221843 A , B 21-02-1990 GR 89100507 A , B 22-08-1990 HK 84196 A 24-05-1996 IE 64524 B1 09-08-1995 IL 91275 A 19-01-1996 IT 1235879 B 23-11-1992 JP 2104522 A 17-04-1990 JP 2810916 B2 15-10-1998 KR 126286 B1 26-12-1997 LU 87570 A1 08-01-1990 NL 8902020 A , B, 01-03-1990 NZ 230022 A 26-10-1990 SE 504742 C2 14-04-1997 SE 8902701 A 12-02-1990 ZA 8905512 A - 25-07-1990
US 5656667	A	12-08-1997	US 5502077 A 26-03-1996 US 5698594 A 16-12-1997 AT 398779 B 25-01-1995 AT 191889 A 15-06-1994 AU 616784 B2 07-11-1991 AU 3896789 A 15-02-1990 BE 1002547 A5 19-03-1991 CA 1337548 C 14-11-1995 CH 680789 A5 13-11-1992 DE 3926658 A1 15-02-1990 DK 392089 A 12-02-1990 ES 2018384 A6 01-04-1991 FI 893805 A 12-02-1990 FR 2635263 A1 16-02-1990 GB 2221843 A , B 21-02-1990 GR 89100507 A , B 22-08-1990 HK 84196 A 24-05-1996 IE 64524 B1 09-08-1995 IL 91275 A 19-01-1996 IT 1235879 B 23-11-1992 JP 2104522 A 17-04-1990 JP 2810916 B2 15-10-1998 KR 126286 B1 26-12-1997 LU 87570 A1 08-01-1990

INTERNATIONAL SEARCH REPORT

 International Application No.
 PCT/IB 03/02317

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5656667 A		NL 8902020 A , B, NZ 230022 A SE 504742 C2 SE 8902701 A ZA 8905512 A	01-03-1990 26-10-1990 14-04-1997 12-02-1990 25-07-1990
US 5698594 A	16-12-1997	US 5656667 A US 5502077 A AT 398779 B AT 191889 A AU 616784 B2 AU 3896789 A BE 1002547 A5 CA 1337548 C CH 680789 A5 DE 3926658 A1 DK 392089 A ES 2018384 A6 FI 893805 A FR 2635263 A1 GB 2221843 A , B GR 89100507 A , B HK 84196 A IE 64524 B1 IL 91275 A IT 1235879 B JP 2104522 A JP 2810916 B2 KR 126286 B1 LU 87570 A1 NL 8902020 A , B, NZ 230022 A SE 504742 C2 SE 8902701 A ZA 8905512 A	12-08-1997 26-03-1996 25-01-1995 15-06-1994 07-11-1991 15-02-1990 19-03-1991 14-11-1995 13-11-1992 15-02-1990 12-02-1990 01-04-1991 12-02-1990 16-02-1990 21-02-1990 22-08-1990 24-05-1996 09-08-1995 19-01-1996 23-11-1992 17-04-1990 15-10-1998 26-12-1997 08-01-1990 01-03-1990 26-10-1990 14-04-1997 12-02-1990 25-07-1990

THIS PAGE BLANK (USPTO)

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 December 2003 (24.12.2003)

PCT

(10) International Publication Number
WO 2003/105822 A1

(51) International Patent Classification⁷: **A61K 31/20**

(21) International Application Number:
PCT/IB2003/002317

(22) International Filing Date: 16 June 2003 (16.06.2003)

(25) Filing Language: Italian

(26) Publication Language: English

(30) Priority Data:
TO2002A000521 17 June 2002 (17.06.2002) IT
TO2002A001049 3 December 2002 (03.12.2002) IT

(71) Applicant (for all designated States except US):
MEDESTEA RESEARCH & PRODUCTION S.R.L.
[IT/IT]; Via Ribes 5, I-10010 Colletterto Giacosa (IT).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **CRAVOTTO, Giancarlo** [IT/IT]; Via Buenos Aires 106, I-10137 Torino (IT).

(74) Agents: **RAMBELLI, Paolo et al.**; Jacobacci & Partners
SpA, Corso Regio Parco 27, I-10152 Torino (IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW),

Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

(48) Date of publication of this corrected version:

8 April 2004


(15) Information about Correction:

see PCT Gazette No. 15/2004 of 8 April 2004, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: LONG CHAIN UNSATURATED OXYGENATED COMPOUNDS AND THEIR USE IN THE THERAPEUTICAL, COSMETIC AND NUTRACEUTICAL FIELD

(57) Abstract: Long-chain unsaturated oxygenated compounds and their use in the therapeutic, cosmetic and nutraceutical field. Use of compounds of formula R-X wherein X is a primary alcoholic functional group -CH₂OH, a carboxylic functional group -COON or a C1-C4 alkyl ester group, and of mono-, di- and tri-glycerides of acid compounds R-COON and of pharmaceutically acceptable salts of those acids, wherein R is a hydrocarbon chain having from 19 to 35 carbon atoms, which is saturated or unsaturated, including from one to five ethylenic or acetylenic unsaturations, linear or branched, including from one to five methyl branches, and optionally substituted by from one to three hydroxyl groups, for the preparation of pharmaceutical or nutraceutical compositions useful for the treatment and prevention of pathologies related to a high concentration of cholesterol and lipids, pathologies associated with an increased ability of the blood platelets to aggregate and with a reduced concentration of oxygen, in the treatment of ageing processes, for the preparation of compositions of nutritional integrators aimed at weight loss and cosmetic compositions useful in the treatment and prevention of skin damage caused by free radicals.



WO 2003/105822 A1

THIS PAGE BLANK (USPTO)